{"protocolSection":{"identificationModule":{"nctId":"NCT01919489","orgStudyIdInfo":{"id":"IRB00068128"},"secondaryIdInfos":[{"id":"(UTN) U1111-1139-2991","type":"REGISTRY","domain":"UNIVERSAL TRIAL NUMBER"}],"organization":{"fullName":"Emory University","class":"OTHER"},"briefTitle":"Liraglutide Hospital Discharge Trial","officialTitle":"A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge"},"statusModule":{"statusVerifiedDate":"2021-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-08-30","type":"ACTUAL"},"completionDateStruct":{"date":"2020-08-30","type":"ACTUAL"},"studyFirstSubmitDate":"2013-07-30","studyFirstSubmitQcDate":"2013-08-07","studyFirstPostDateStruct":{"date":"2013-08-09","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-08-30","resultsFirstSubmitQcDate":"2021-10-05","resultsFirstPostDateStruct":{"date":"2021-11-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-10-05","lastUpdatePostDateStruct":{"date":"2021-11-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Guillermo Umpierrez, MD","investigatorTitle":"Professor of Medicine","investigatorAffiliation":"Emory University"},"leadSponsor":{"name":"Emory University","class":"OTHER"},"collaborators":[{"name":"Novo Nordisk A/S","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the hospital complications. Increasing evidence indicates that incretin-based agents are safe and effective for the hospital management of patients with type 2 diabetes (T2D).\n\nLiraglutide is a once-daily human glucagon-like peptide (GLP-1) analogue approved for the treatment of T2D. Liraglutide has been shown to lower blood glucose, stimulate endogenous insulin secretion, decrease plasma glucagon levels, inhibit gastric emptying, reduce food intake and body weight and improve ß-cell function when administered subcutaneously. Liraglutide increases insulin secretion in a glucose-dependent manner (i.e., only when plasma glucose levels are elevated), resulting in low-risk of hypoglycemia when used as monotherapy. When compared to insulin glargine therapy, the use of GLP-1 has resulted in comparable reduction in HbA1c level, lower rates of hypoglycemia and less weight gain. No prospective studies; however, have compared the efficacy and safety of liraglutide in the hospital setting or after hospital discharge.\n\nThe primary objective is to compare the safety and efficacy of liraglutide (Victoza®) versus glargine insulin in combination to oral anti-diabetic agents (OADs: metformin, sulfonylureas, nateglinide, repaglinide or pioglitazone) on glycemic control after 26 weeks of treatment in medicine patients with T2D after hospital discharge.","detailedDescription":"Specific Aim: To determine whether treatment with liraglutide (Victoza®) will result in similar glycemic control (HbA1c at 26 weeks) and a lower rate of hypoglycemic events compared to treatment with glargine (Lantus®) in patients with T2D after hospital discharge. Patients with poorly controlled (HbA1c \\>7%-10%) T2D treated with diet or oral antidiabetic agents or low dose insulin naïve (0.4u/kg/day) prior to admission will be randomized to liraglutide or glargine in combination to OADs at hospital discharge."},"conditionsModule":{"conditions":["Type 2 Diabetes"],"keywords":["Incretins","Liraglutide","Glargine","Randomized controlled trial","basal insulin","hospital discharge","inpatient diabetes"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":273,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Liraglutide + OADs","type":"EXPERIMENTAL","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)","interventionNames":["Drug: Liraglutide + OADs"]},{"label":"Glargine + OADs","type":"ACTIVE_COMPARATOR","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)","interventionNames":["Drug: Glargine + OADs"]}],"interventions":[{"type":"DRUG","name":"Liraglutide + OADs","description":"Liraglutide subcutaneously daily","armGroupLabels":["Liraglutide + OADs"],"otherNames":["Victoza® + OADs"]},{"type":"DRUG","name":"Glargine + OADs","description":"Glargine once daily subcutaneously","armGroupLabels":["Glargine + OADs"],"otherNames":["Glargine (Lantus®) + OADs"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Glycemic Control at Hospital Discharge and 6 Months Follow up","description":"To determine differences in HbA1c concentration at 26 weeks from discharge between liraglutide and glargine insulin therapy","timeFrame":"Hospital discharge, 6 months (26 weeks)"}],"secondaryOutcomes":[{"measure":"Fasting and Postprandial Blood Glucose (BG) Concentration After Follow up of 26 Weeks","description":"To determine differences in BG concentration between liraglutide and glargine insulin therapy","timeFrame":"After discharge, average at 3 months (12 week) and 6 months (26 weeks)"},{"measure":"Hypoglycemic Episodes","description":"Number of participants who had at least one hypoglycemic event (\\<70 mg/dl) and severe hypoglycemic event (\\<40 mg/dl)","timeFrame":"After discharge, average 6 months"},{"measure":"HbA1c <7.0% and no Hypoglycemia","description":"Percent of patients with 26 week HbA1c \\<7.0% and no hypoglycemia","timeFrame":"After discharge, average 6 months"},{"measure":"HbA1c <7.0% and no Weight Gain","description":"Percent of patients with 26 week HbA1c \\<7.0% and no weight gain","timeFrame":"After discharge, average 6 months"},{"measure":"HbA1c <7.0% and no Hypoglycemia","description":"Percent of patients with 12 week HbA1c \\<7.0% and no hypoglycemia","timeFrame":"After discharge, average 12 weeks"},{"measure":"Change in Body Weight From Baseline","description":"Change in body weight from baseline after 6 months of follow up (26 weeks)","timeFrame":"After discharge, average 6 months"},{"measure":"Change in BMI","description":"Change in BMI after 6 months from baseline","timeFrame":"Baseline, and follow up after discharge (average 6 months)"},{"measure":"Total Daily Dose of Insulin","description":"Evaluate the total daily dose of insulin needed in the group receiving glargine","timeFrame":"After discharge, average 6 months"},{"measure":"Change in Cardiovascular Risk Factors: Blood Pressure","description":"Cardiovascular risk factors including changes in systolic and diastolic blood pressure from baseline to 26 weeks post-intervention","timeFrame":"Baseline, 26 weeks post-intervention"},{"measure":"Cardiovascular Risk Factor: Heart Rate","description":"Cardiovascular risk: heart rate at baseline and 26 weeks post-intervention","timeFrame":"26 weeks post-intervention"},{"measure":"Cardiovascular Risk Factor: Lipid Profile","description":"Lipid profile was measured with total cholesterol level results at 26 weeks post-intervention. This outcome was not part of standard of care.","timeFrame":"26 weeks post-intervention"},{"measure":"Emergency Room Visits and Readmissions","description":"Number of participants who had at least one emergency room visit and hospital readmissions","timeFrame":"After discharge, average 6 months"},{"measure":"Acute Renal Failure","description":"Acute renal failure during the 26-week follow-up defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment in creatinine \\> 0.5 mg/dL from baseline)","timeFrame":"After discharge, average 6 months"},{"measure":"Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up","description":"Number of participants that reported self-measured blood glucose (SMBG) 7-point profiles at 26 weeks follow up","timeFrame":"26 weeks post-intervention"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males or females between the ages of 18 and 80 years discharged after hospital admission from non- ICU general surgery and medicine services (excluding gastrointestinal and cardiac surgeries).\n2. Admission HbA1c between 7% and 10%\n3. Patients with T2D treated with diet alone or with oral antidiabetic agents as monotherapy or in combination therapy (excluding GLP1 receptor agonists) or on low-dose insulin therapy (TDD ≤0.4 unit/kg/day) prior to admission.\n4. Subjects with a hospital admission BG \\< 400 mg/dL without laboratory evidence of diabetic ketoacidosis (serum bicarbonate \\< 18 mEq/L or positive serum or urinary ketones).\n5. BMI \\> 25 Kg/m2 and ≤ 45 Kg/m2\n\nExclusion Criteria:\n\n1. Age \\< 18 or \\> 80 years.\n2. Subjects with stress hyperglycemia (BG \\> 140 mg/dL and HbA1c \\< 6.5%)\n3. Subjects with a history of type 1 diabetes\n4. Treatment with insulin or GLP-1 analogs during the past 3 months prior to admission.\n5. Recurrent severe hypoglycemia or hypoglycemic unawareness.\n6. Subjects with gastrointestinal obstruction, gastroparesis, or those expected to require gastrointestinal suction.\n7. History of medullary thyroid cancer or multiple endocrine neoplasias\n8. Patients with acute or chronic pancreatitis, pancreatic cancer, or gallbladder disease.\n9. Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage liver disease, portal hypertension) and elevated ALT and AST \\> 3 times upper limit of normal, or significantly impaired renal function (GFR \\< 30 ml/min).\n10. Treatment with oral or injectable corticosteroid (equivalent or higher than prednisone 5mg/day), parenteral nutrition, and immunosuppressive treatment.\n11. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.\n12. Female subjects who are pregnant or breastfeeding at the time of enrollment into the study.\n13. Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Guillermo E Umpierrez, MD","affiliation":"Emory University SOM","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of Miami","city":"Miami","state":"Florida","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Grady Memorial Hospital","city":"Atlanta","state":"Georgia","zip":"30303","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Emory University Hospital","city":"Atlanta","state":"Georgia","zip":"30324","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Emory Universtiy Hospital at MIdtown","city":"Atlanta","state":"Georgia","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"State University of NY at Buffalo","city":"New York","state":"New York","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"FG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"136"},{"groupId":"FG001","numSubjects":"137"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"80"},{"groupId":"FG001","numSubjects":"93"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"44"}]}],"dropWithdraws":[{"type":"Rejected the need of injections","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Hospital readmission","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"27"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"BG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"136"},{"groupId":"BG001","value":"137"},{"groupId":"BG002","value":"273"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.1","spread":"9.5"},{"groupId":"BG001","value":"55.9","spread":"11.2"},{"groupId":"BG002","value":"56.1","spread":"10.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"108"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"165"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"192"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"50"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"31"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"267"}]}]},{"title":"Argentina","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Glycemic Control at Hospital Discharge and 6 Months Follow up","description":"To determine differences in HbA1c concentration at 26 weeks from discharge between liraglutide and glargine insulin therapy","populationDescription":"Number of subjects analyzed at 6 months differs from overall number of subjects analyzed, due to patients unable to complete the trial: 56 in the Liraglutide Arm and 44 in the Glargine Arm.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"% (mmol/mol)","timeFrame":"Hospital discharge, 6 months (26 weeks)","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"classes":[{"title":"HbA1C at hospital discharge","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"0.9"},{"groupId":"OG001","value":"8.4","spread":"0.8"}]}]},{"title":"HbA1C at 6 months post-intervention","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"93"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.13","spread":"1.3"},{"groupId":"OG001","value":"7.68","spread":"1.69"}]}]}]},{"type":"SECONDARY","title":"Fasting and Postprandial Blood Glucose (BG) Concentration After Follow up of 26 Weeks","description":"To determine differences in BG concentration between liraglutide and glargine insulin therapy","populationDescription":"The number of subjects analyzed in this outcome at different time points from the overall number of subjects analyzed in other timepoints because it includes only those participants who were able to provide blood glucose results at the specified time points reported (12 and 26 weeks).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"After discharge, average at 3 months (12 week) and 6 months (26 weeks)","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"79"}]}],"classes":[{"title":"Fasting blood glucose at 26 weeks follow up","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.61","spread":"2.2"},{"groupId":"OG001","value":"8.56","spread":"3.8"}]}]},{"title":"Post-prandial blood glucose at 12 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.67","spread":"1.6"},{"groupId":"OG001","value":"9.32","spread":"8.8"}]}]},{"title":"Postprandial blood glucose at 26 weeks follow up","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.23","spread":"2.8"},{"groupId":"OG001","value":"8.72","spread":"2.3"}]}]},{"title":"Fasting blood glucose at 12 weeks","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.96","spread":"3.3"},{"groupId":"OG001","value":"7.70","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Hypoglycemic Episodes","description":"Number of participants who had at least one hypoglycemic event (\\<70 mg/dl) and severe hypoglycemic event (\\<40 mg/dl)","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"After discharge, average 6 months","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"classes":[{"title":"Participants who had at least one hypoglycemic events (<70 mg/dl)","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"31"}]}]},{"title":"Participants who had at least one severe hypoglycemic event (<40 mg/dl)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"HbA1c <7.0% and no Hypoglycemia","description":"Percent of patients with 26 week HbA1c \\<7.0% and no hypoglycemia","populationDescription":"This outcome included only participants with available data for both variables: HbA1c and hypoglycemia","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"After discharge, average 6 months","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"29"}]}]}]},{"type":"SECONDARY","title":"HbA1c <7.0% and no Weight Gain","description":"Percent of patients with 26 week HbA1c \\<7.0% and no weight gain","populationDescription":"This outcome included only participants with available data for both variables: HbA1c and weight","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"After discharge, average 6 months","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"90"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"21"}]}]}]},{"type":"SECONDARY","title":"HbA1c <7.0% and no Hypoglycemia","description":"Percent of patients with 12 week HbA1c \\<7.0% and no hypoglycemia","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"After discharge, average 12 weeks","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"94"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"31"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline","description":"Change in body weight from baseline after 6 months of follow up (26 weeks)","populationDescription":"This outcome only included participants with available data for body weight in Kgs at baseline and 26 weeks follow up.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kgs","timeFrame":"After discharge, average 6 months","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"91"}]}],"classes":[{"title":"Baseline weight at discharge","categories":[{"measurements":[{"groupId":"OG000","value":"101.0","spread":"20.6"},{"groupId":"OG001","value":"98.2","spread":"18.0"}]}]},{"title":"Weight at six months","categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":"19.9"},{"groupId":"OG001","value":"98.3","spread":"22.1"}]}]},{"title":"Weight change from baseline (discharge) to 6 months after discharge","categories":[{"measurements":[{"groupId":"OG000","value":"-4.77","spread":"8"},{"groupId":"OG001","value":"0.6","spread":"11"}]}]}]},{"type":"SECONDARY","title":"Change in BMI","description":"Change in BMI after 6 months from baseline","populationDescription":"This outcome only included participants with available data for BMI at baseline and follow up of 26 weeks.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kg/m2","timeFrame":"Baseline, and follow up after discharge (average 6 months)","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"classes":[{"title":"Baseline BMI","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","spread":"5.3"},{"groupId":"OG001","value":"33.3","spread":"5.3"}]}]},{"title":"BMI at 26 weeks follow up","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"91"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":"6.8"},{"groupId":"OG001","value":"33.3","spread":"6.2"}]}]}]},{"type":"SECONDARY","title":"Total Daily Dose of Insulin","description":"Evaluate the total daily dose of insulin needed in the group receiving glargine","populationDescription":"This outcome analyzed participants with available medication dose for the 26 weeks follow up.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"IU per day","timeFrame":"After discharge, average 6 months","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"90"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"20.9","spread":"11.1"}]}]}]},{"type":"SECONDARY","title":"Change in Cardiovascular Risk Factors: Blood Pressure","description":"Cardiovascular risk factors including changes in systolic and diastolic blood pressure from baseline to 26 weeks post-intervention","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Baseline, 26 weeks post-intervention","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Systolic blood pressure at baseline","categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":"17"},{"groupId":"OG001","value":"130","spread":"17"}]}]},{"title":"Systolic blood pressure at 26 weeks follow up","categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":"22"},{"groupId":"OG001","value":"135","spread":"19"}]}]},{"title":"Diastolic blood pressure at baseline","categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":"11"},{"groupId":"OG001","value":"77","spread":"12"}]}]},{"title":"Diastolic blood pressure at 26 weeks follow up","categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":"13"},{"groupId":"OG001","value":"79","spread":"14"}]}]}]},{"type":"SECONDARY","title":"Cardiovascular Risk Factor: Heart Rate","description":"Cardiovascular risk: heart rate at baseline and 26 weeks post-intervention","populationDescription":"This outcome included patients with available heart rate data at 26 weeks follow-up.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats/min","timeFrame":"26 weeks post-intervention","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Heart rate at baseline (discharge)","categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":"14"},{"groupId":"OG001","value":"79","spread":"14"}]}]},{"title":"Heart rate at 6 months post-discharge","categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":"13"},{"groupId":"OG001","value":"79","spread":"14"}]}]}]},{"type":"SECONDARY","title":"Cardiovascular Risk Factor: Lipid Profile","description":"Lipid profile was measured with total cholesterol level results at 26 weeks post-intervention. This outcome was not part of standard of care.","populationDescription":"Total cholesterol was measured in 9 subjects only due to limited funding.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/dL","timeFrame":"26 weeks post-intervention","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":"6"},{"groupId":"OG001","value":"130","spread":"56"}]}]}]},{"type":"SECONDARY","title":"Emergency Room Visits and Readmissions","description":"Number of participants who had at least one emergency room visit and hospital readmissions","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"After discharge, average 6 months","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"classes":[{"title":"Number of participants with at least one ER visit","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"23"}]}]},{"title":"Number of participants with at least one hospital readmission","categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"43"}]}]}]},{"type":"SECONDARY","title":"Acute Renal Failure","description":"Acute renal failure during the 26-week follow-up defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment in creatinine \\> 0.5 mg/dL from baseline)","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"After discharge, average 6 months","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up","description":"Number of participants that reported self-measured blood glucose (SMBG) 7-point profiles at 26 weeks follow up","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"26 weeks post-intervention","groups":[{"id":"OG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily"},{"id":"OG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"34"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Data collected during follow up (6 months post-intervention).","eventGroups":[{"id":"EG000","title":"Liraglutide + OADs","description":"Liraglutide once daily in combination to oral anti-diabetic agents (OADs)\n\nLiraglutide + OADs: Liraglutide subcutaneously daily","deathsNumAffected":2,"deathsNumAtRisk":136,"seriousNumAffected":52,"seriousNumAtRisk":136,"otherNumAffected":0,"otherNumAtRisk":136},{"id":"EG001","title":"Glargine + OADs","description":"Glargine once daily in combination to oral anti-diabetic agents (OADs)\n\nGlargine + OADs: Glargine once daily subcutaneously","deathsNumAffected":1,"deathsNumAtRisk":137,"seriousNumAffected":54,"seriousNumAtRisk":137,"otherNumAffected":0,"otherNumAtRisk":137}],"seriousEvents":[{"term":"Readmissions","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":35,"numAtRisk":136},{"groupId":"EG001","numEvents":94,"numAffected":43,"numAtRisk":137}]},{"term":"Congestive heart failure","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":12,"numAtRisk":136},{"groupId":"EG001","numEvents":34,"numAffected":13,"numAtRisk":137}]},{"term":"Medication discontinued due to AEs","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":136},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]},{"term":"Cerebrovascular event","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":136},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":136},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":136},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":137}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":37,"numAtRisk":136},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":137}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":136},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":137}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dr. Francisco Pasquel","organization":"Emory University","email":"fpasque@emory.edu","phone":"404-778-1695"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2019-10-28","uploadDate":"2021-08-19T14:35","filename":"Prot_SAP_000.pdf","size":374188}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","removedCountries":["Spain"]},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069450","term":"Liraglutide"},{"id":"D000069036","term":"Insulin Glargine"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"},{"id":"D049528","term":"Insulin, Long-Acting"},{"id":"D061385","term":"Insulins"},{"id":"D010187","term":"Pancreatic Hormones"},{"id":"D036361","term":"Peptide Hormones"},{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"}]}},"hasResults":true}